Barclays PLC Syndax Pharmaceuticals Inc Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 196,051 shares of SNDX stock, worth $2.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

196,051

Previous 187,629 4.49%

Holding current value

$2.69 Million

Previous $3.61 Million 28.24%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$12.52 - $21.81 $105,443 - $183,683	8,422 Added 4.49%	196,051 $2.59 Million
Q3 2024 Nov 15, 2024	BUY	$17.93 - $24.81 $1.98 Million - $2.74 Million	110,535 Added 143.38%	187,629 $3.61 Million
Q2 2024 Aug 14, 2024	SELL	$18.82 - $23.79 $471,967 - $596,605	-25,078 Reduced 24.54%	77,094 $1.58 Million
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $3.03 Million - $3.78 Million	-153,705 Reduced 60.07%	102,172 $2.43 Million
Q4 2023 Feb 15, 2024	SELL	$11.39 - $21.67 $1.89 Million - $3.6 Million	-166,131 Reduced 39.37%	255,877 $5.53 Million
Q3 2023 Nov 07, 2023	BUY	$14.52 - $21.77 $3.67 Million - $5.5 Million	252,813 Added 149.42%	422,008 $6.13 Million
Q2 2023 Aug 03, 2023	SELL	$19.35 - $22.31 $15.7 Million - $18.1 Million	-812,691 Reduced 82.77%	169,195 $3.54 Million
Q1 2023 May 04, 2023	BUY	$20.66 - $28.98 $383,243 - $537,579	18,550 Added 1.93%	981,886 $20.7 Million
Q4 2022 Feb 13, 2023	BUY	$20.64 - $26.24 $14.2 Million - $18 Million	687,577 Added 249.34%	963,336 $24.5 Million
Q3 2022 Nov 03, 2022	BUY	$18.51 - $24.79 $5.02 Million - $6.72 Million	271,168 Added 5906.51%	275,759 $6.63 Million
Q2 2022 Aug 12, 2022	SELL	$13.64 - $19.48 $949,930 - $1.36 Million	-69,643 Reduced 93.82%	4,591 $88,000
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $10.4 Million - $15.5 Million	-701,242 Reduced 90.43%	74,234 $1.29 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $5.68 Million - $8.38 Million	373,088 Added 92.72%	775,476 $17 Million
Q3 2021 Nov 09, 2021	BUY	$13.87 - $19.8 $4.79 Million - $6.83 Million	345,050 Added 601.78%	402,388 $7.69 Million
Q2 2021 Aug 13, 2021	SELL	$13.42 - $25.18 $198,897 - $373,192	-14,821 Reduced 20.54%	57,338 $984,000
Q1 2021 May 13, 2021	BUY	$19.28 - $24.59 $1.19 Million - $1.52 Million	61,976 Added 608.62%	72,159 $1.61 Million
Q4 2020 Feb 11, 2021	SELL	$15.1 - $26.44 $46,221 - $80,932	-3,061 Reduced 23.11%	10,183 $226,000
Q3 2020 Nov 12, 2020	SELL	$13.39 - $17.48 $487,449 - $636,341	-36,404 Reduced 73.32%	13,244 $196,000
Q2 2020 Aug 12, 2020	BUY	$8.94 - $20.98 $363,920 - $854,032	40,707 Added 455.28%	49,648 $736,000
Q1 2020 May 13, 2020	SELL	$6.65 - $12.03 $106,400 - $192,480	-16,000 Reduced 64.15%	8,941 $99,000
Q4 2019 Feb 10, 2020	BUY	$5.43 - $9.22 $54,283 - $92,172	9,997 Added 66.9%	24,941 $218,000
Q3 2019 Nov 14, 2019	SELL	$7.47 - $10.76 $21,521 - $30,999	-2,881 Reduced 16.16%	14,944 $111,000
Q2 2019 Aug 14, 2019	BUY	$4.9 - $9.31 $42,154 - $80,093	8,603 Added 93.29%	17,825 $167,000
Q1 2019 May 15, 2019	SELL	$4.26 - $6.86 $11,203 - $18,041	-2,630 Reduced 22.19%	9,222 $48,000
Q4 2018 Feb 14, 2019	SELL	$3.6 - $8.42 $21,891 - $51,202	-6,081 Reduced 33.91%	11,852 $52,000
Q3 2018 Nov 14, 2018	BUY	$6.33 - $8.08 $48,987 - $62,531	7,739 Added 75.92%	17,933 $144,000
Q2 2018 Aug 14, 2018	BUY	$6.93 - $14.63 $18,932 - $39,969	2,732 Added 36.61%	10,194 $72,000
Q1 2018 May 15, 2018	BUY	$8.71 - $14.82 $6,837 - $11,633	785 Added 11.76%	7,462 $106,000
Q4 2017 Feb 14, 2018	SELL	$7.8 - $12.94 $60,270 - $99,987	-7,727 Reduced 53.64%	6,677 $58,000
Q3 2017 Nov 14, 2017	BUY	$10.9 - $12.73 $157,003 - $183,362	14,404	14,404 $168,000

Others Institutions Holding SNDX

# of Institutions

233

Shares Held

96.9M

Call Options Held

1.39M

Put Options Held

543K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $776M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account